De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era

Allison J. Kwong, W. Ray Kim, Jennifer A. Flemming – 19 April 2018 – The risk of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) receiving direct acting antivirals (DAAs) has been debated. This study aims to describe the incidence of HCC among patients listed for liver transplantation (LT) in the DAA era. Individuals with cirrhosis listed for LT from January 2003 to December 2015 were identified using the Scientific Registry for Transplant Recipients database. Patients with HCC at listing or HCC exception within 180 days were excluded.

Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy

Alexander Lemmer, Lisa B. VanWagner, Daniel Ganger – 19 April 2018 – Congestive hepatopathy (CH) arises from chronically elevated right‐sided heart pressures transmitted to the liver by passive venous congestion. Over time, CH can lead to hepatic bridging fibrosis, decompensated cirrhosis, and hepatocellular carcinoma.

Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy

Alexander Lemmer, Lisa B. VanWagner, Daniel Ganger – 19 April 2018 – Congestive hepatopathy (CH) arises from chronically elevated right‐sided heart pressures transmitted to the liver by passive venous congestion. Over time, CH can lead to hepatic bridging fibrosis, decompensated cirrhosis, and hepatocellular carcinoma.

Clinical application of the GLOBE and United Kingdom‐primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis

Marco Carbone, Maren H. Harms, Willem J. Lammers, Tonya Marmon, Richard Pencek, Leigh MacConell, David Shapiro, David E. Jones, George F. Mells, Bettina E. Hansen – 19 April 2018 – The GLOBAL Primary Biliary Cholangitis (PBC) Study Group and United Kingdom‐PBC (UK‐PBC) Consortium have demonstrated that dichotomous response criteria are not as accurate as continuous equations at predicting mortality or liver transplantation in PBC.

Oxidatively Modified Protein‐Disulfide Isomerase–Associated 3 Promotes Dyskerin Pseudouridine Synthase 1–Mediated Malignancy and Survival of Hepatocellular Carcinoma Cells

Eunkyong Ko, Jong‐Seo Kim, Soomi Ju, Hyun‐Wook Seo, Yeonji Chang, Jung‐Ah Kang, Sung‐Gyoo Park, Guhung Jung – 19 April 2018 – Dyskerin pseudouridine synthase 1 (DKC1) is a conserved gene encoding the RNA‐binding protein dyskerin, which is an essential component of the telomerase holoenzyme. DKC1 up‐regulation is frequently observed in many different human cancers including hepatocellular carcinoma (HCC); however, its regulatory mechanisms remain unclear. Thus, we investigated the regulatory mechanism of DKC1 in HCC progression.

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Nancy Reau, Paul Y. Kwo, Susan Rhee, Robert S. Brown, Kosh Agarwal, Peter Angus, Edward Gane, Jia‐Horng Kao, Parvez S. Mantry, David Mutimer, K. Rajender Reddy, Tram T. Tran, Yiran B. Hu, Abhishek Gulati, Preethi Krishnan, Emily O. Dumas, Ariel Porcalla, Nancy S. Shulman, Wei Liu, Suvajit Samanta, Roger Trinh, Xavier Forns – 19 April 2018 – Well‐tolerated, ribavirin‐free, pangenotypic hepatitis C virus (HCV) treatments for transplant recipients remain a high priority.

Subscribe to